APA (7th ed.) Citation

Wu, Y., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., . . . Mok, T. S. (2017). Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial. Lancet Oncology, 18(11), 1454. https://doi.org/10.1016/S1470-2045(17)30608-3

Chicago Style (17th ed.) Citation

Wu, Yi-Long, et al. "Dacomitinib Versus Gefitinib as First-line Treatment for Patients with EGFR-mutation-positive Non-small-cell Lung Cancer (ARCHER 1050): A Randomised, Open-label, Phase 3 Trial." Lancet Oncology 18, no. 11 (2017): 1454. https://doi.org/10.1016/S1470-2045(17)30608-3.

MLA (9th ed.) Citation

Wu, Yi-Long, et al. "Dacomitinib Versus Gefitinib as First-line Treatment for Patients with EGFR-mutation-positive Non-small-cell Lung Cancer (ARCHER 1050): A Randomised, Open-label, Phase 3 Trial." Lancet Oncology, vol. 18, no. 11, 2017, p. 1454, https://doi.org/10.1016/S1470-2045(17)30608-3.